Company · Private
Rubedo Life Sciences
Uses a chemistry platform to design prodrugs activated inside senescent cells, aiming for tissue-selective clearance.
EvidenceEarly
Listing
Private
Ticker
—
Headquarters
Sunnyvale, US
Founded
2019
Technology
Selective senolytic prodrugs
Category
Market cap
Private
Longevity thesis
Selectivity, not potency, is the limiting factor for systemic senolytics.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| RLS-1496 | Phase 1 | Dermatology and fibrosis |
Recent developments
- 22 Apr 2026Completed Phase 1 dose escalation.
Scientific evidence
EvidenceEarly
Early human safety data; efficacy unproven.
LONGEFI analysis
Chemistry-led approach that would benefit disproportionately from any positive senolytic readout elsewhere in the field.
Analysis is research commentary. It is not investment advice or a recommendation.